PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Pegzilarginase→

Pegzilarginase PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~150000 g/mol
Drug class
Recombinant human arginase 1 enzyme replacement therapyarginine-depleting biologic
Mechanism of action
Provides exogenous arginase 1 activity, converting excess arginine to urea and ornithine and thereby lowering plasma arginine in patients with arginase 1 deficiency.
Indications / reported uses
  • Treatment of hyperargininaemia in adults and paediatric patients aged 2 years and older with arginase 1 deficiency, in conjunction with dietary protein restriction, under the current product label.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5ceabf2-43a0-4746-9371-d98a39cf6cfc · https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/761211Orig1s000IntegratedR.pdf

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Pegzilarginase PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pegzilarginase Permitted Daily Exposure (PDE) report (the Pegzilarginase PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pegzilarginase Occupational Exposure Limit (OEL) report (the Pegzilarginase OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.